anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Fraud Exposure

Framework collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 6,793
Current window 5,281-5,310
Pages 227
Rows per page 30
Framework: Fraud Exposureclear collectionreset all
18 30 60

Framework

5,281-5,310 of 6,793

filter-aware
127
Uses direct quotes from interviews to build a case of fraud/misrepresentation.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Beat · Critique of Quantumscape's claims and technology1 hit
129
The slide uses a combination of expert quote and academic citation to frame the company's claims as fraudulent.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Beat · Critique of Quantumscape's claims and technology1 hit
130
The slide uses a Q&A format to expose a fundamental flaw in the company's technology claims.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Beat · Critique of Quantumscape's claims and technology1 hit
131
Uses direct quotes from a former employee to frame the company's technology as physically unfeasible.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Beat · Critique of Quantumscape's claims and technology1 hit
134
The slide uses a red-circled chart to illustrate the 'sleight of hand' in data presentation.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Beat · Critique of Quantumscape's claims and technology1 hit
135
Includes expert commentary on technical limitations of multi-layer pouch cells.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Beat · Critique of Quantumscape's claims and technology1 hit
136
The slide uses a red arrow and annotation to point out the small sample size in the provided chart.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Beat · Critique of Quantumscape's claims and technology1 hit
140
Uses highlighted text to emphasize key skeptical points from former employees.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Beat · Critique of Quantumscape's claims and technology1 hit
146
The slide uses expert testimony to expose a technical contradiction in the company's claims.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Beat · Critique of Quantumscape's claims and technology1 hit
147
Uses a combination of a chart from a company presentation and direct quotes from an SEC 10K filing to highlight a discrepancy.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Beat · Critique of Quantumscape's claims and technology1 hit
151
Uses expert testimony and external media citations to undermine the company's technical viability.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Loop · Cost Of Inaction1 hit
158
The slide uses a 'villain' narrative by citing an ex-employee to undermine the company's core value proposition.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Loop · Cost Of Inaction1 hit
162
Uses a screenshot of a Medium article to provide external validation for the claim of systemic fraud.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Loop · Cost Of Inaction1 hit
164
The slide uses an external industry standard (Joule Battery Checklist) as a benchmark to critique the target company's lack of transparency.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Loop · Cost Of Inaction1 hit
166
The slide uses a series of news headlines to build a pattern of recurring fraud in the battery sector.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Loop · Cost Of Inaction1 hit
173
The slide uses a 'before-after' style comparison to frame Quantumscape as a repeat of the Sakti3 fraud.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Loop · Cost Of Inaction1 hit
175
Uses a series of source citations and quotes to build a narrative of investor negligence or deception.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Loop · Cost Of Inaction1 hit
179
Uses SEC filing excerpts and a Notice of Effectiveness screenshot as evidence of insider dumping.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Loop · Cost Of Inaction1 hit
181
Uses historical precedent (Infinera) to cast doubt on current QS insiders; includes red dashed circles highlighting zero-balance positions.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Loop · Cost Of Inaction1 hit
183
The slide uses red boxes and arrows to draw attention to specific, aggressive growth figures in the financial table.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Loop · Cost Of Inaction1 hit
03
The slide uses anonymous expert testimony to undermine the company's clinical trial integrity and market prospects.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
07
The slide uses a screenshot of a Facebook post to undermine the clinical trial results of the drug VYKAT.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
13
Uses anecdotal evidence from Facebook groups to build a case for systemic safety issues.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
16
Uses direct quotes from Facebook posts to highlight patient safety concerns.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
17
The slide highlights a discrepancy between the FDA label's explicit warnings about DKA and the company's omission of this risk in their phase 3 and open-label manuscripts.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
20
The slide uses direct excerpts from a medical paper to build a case against the drug's safety profile.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
02
This is a text-heavy regulatory filing document, likely part of a petition to the FDA regarding safety concerns.Soleno Therapeutics (SLNO) · Kir Kahlon
Regulatory filing Short seller Beat · Problem & Complication1 hit
03
This appears to be a page from a regulatory filing or activist short report, focusing on adverse event reporting and potential obfuscation by the manufacturer.Soleno Therapeutics (SLNO) · Kir Kahlon
Regulatory filing Short seller Beat · Problem & Complication1 hit
05
The slide is a text-heavy regulatory filing page, likely part of a petition or formal complaint. It uses numbered points to build a case of scientific misconduct.Soleno Therapeutics (SLNO) · Kir Kahlon
Regulatory filing Short seller Beat · Problem & Complication1 hit
06
This appears to be a page from an activist short report or regulatory challenge document.Soleno Therapeutics (SLNO) · Kir Kahlon
Regulatory filing Short seller Beat · Desire1 hit